Novartis Ag And Anr. v. Mehar Pharma And Anr.

In the high-stakes world of pharmaceuticals, patent battles can mean life or death—literally. When a multinational drug giant claims exclusive rights to a cancer medication, and a domestic manufacturer steps in to make it affordable, who should the courts side with? This landmark dispute between Novartis AG and Mehar Pharma forced the judiciary to confront a deeply uncomfortable question: can the law protect corporate exclusivity when doing so might cut off a life-saving drug from the patients who need it most?

Novartis AG, a global pharmaceutical powerhouse, held Exclusive Marketing Rights (EMR) for the 'B-crystalline form of imatinib Mesylate salt'—the active compound used in a breakthrough anti-cancer drug. These exclusive rights gave Novartis the legal authority to be the sole marketer of this formulation in India. Meanwhile, Mehar Pharma, an Indian pharmaceutical company, began manufacturing, selling, and exporting its own version of the anti-cancer drug under the brand name 'VEENAT'. Novartis viewed this as a direct infringement of its exclusive marketing rights and moved swiftly to seek legal recourse. The stage was set for a confrontation that would pit international intellectual property claims against domestic public health imperatives.

Novartis argued that Mehar Pharma's production and distribution of 'VEENAT' violated its Exclusive Marketing Rights for the B-crystalline form of imatinib Mesylate salt. As the holder of these exclusive rights, Novartis contended that no other entity should be permitted to market this specific formulation without authorization. On the other side, Mehar Pharma defended its right to manufacture and supply the drug, emphasizing its critical role in making the anti-cancer medication accessible to patients in India. The core legal friction was not merely about intellectual property—it was about whether the court should enforce exclusive marketing rights at the potential cost of disrupting the supply chain of a drug that cancer patients relied upon for their treatment and survival.

On 23 December 2004, the court delivered its decision, and it was not what Novartis had hoped for. The court denied Novartis's request for an interim injunction, effectively allowing Mehar Pharma to continue manufacturing, selling, and exporting 'VEENAT'. The court's reasoning centered on a critical balancing act: the granting of a temporary injunction must carefully weigh the interests of both parties, particularly when the drug in question is essential or life-saving. The court recognized that one party was an importer while the other was a domestic manufacturer, and disrupting the supply of this anti-cancer medication could have devastating consequences for patients who depended on it. By denying the injunction, the court prioritized the continuity of access to a life-saving drug over the enforcement of exclusive marketing rights—at least at the interim stage.

For founders, startup leaders, and IP professionals, this case delivers a powerful lesson: exclusive rights and patents, no matter how strongly held, are not absolute shields—especially in sectors where public health is at stake. If your business operates in pharmaceuticals or any essential goods sector, understand that courts may weigh the broader social impact of injunctions heavily. Before pursuing aggressive interim relief, consider whether your product is life-saving or essential, and whether the opposing party serves a critical role in the supply chain. Strategic litigation is not just about legal entitlement; it is about anticipating how courts will balance commercial rights against public welfare. Build your IP strategy with this reality in mind.